Navigation Links
Unlikely Drugs Emerge as 'Cognition Enhancers'
Date:4/9/2008

Medications to treat ADHD, heart problems becoming popular, survey finds

WEDNESDAY, April 9 (HealthDay News) -- One in five respondents to a new survey acknowledges using so-called "cognition-enhancing drugs" -- such as ADHD and heart medications -- to stimulate their focus, concentration or memory.

The most popular drug was Ritalin (methylphenidate), which is prescribed to treat attention deficit hyperactivity disorder, but has emerged in recent years as a campus "study aid." Coming in second was the stimulant Provigil (modafinil), followed by blood-pressure drugs called beta blockers, which can also help to reduce anxiety.

The online survey was open to subscribers of Nature -- who tend to be researchers and scientists -- and the results are published in the April 10 issue of the scientific journal. The survey found that people of all ages are using these drugs for cognitive enhancement.

That flies in the face of conventional wisdom that suggests stimulant use is highest among people 18 to 25 years old and students, Dr. Nora Volkow, director of the U.S. National Institute on Drug Abuse, noted in the report.

Ritalin was the most popular drug, with 62 percent of users reporting having taken it. Forty-four percent of the respondents -- more than 1,400 people from 60 countries -- said they'd taken Provigil, while 15 percent said they'd taken beta blockers such as propanolol.

Other popular drugs of choice included adderall, an amphetamine similar to Ritalin; centrophenoxine, which is used to treat dementia; and dexedrine, an amphetamine. Supplements such as ginkgo and omega-3 fatty acids were also commonly used, according to the poll.

One third of those using drugs for non-medical purposes said they'd bought them over the Internet. Others got them from pharmacies or with a prescription, according to the survey

The most common reason given for taking any of these drugs was to boost concentration. Combating jet lag was another frequent reason cited by the respondents.

Eighty-six percent of the respondents said they thought children under 16 years of age should be prevented from using these drugs. But one third said they'd feel pressured to give the drugs to their children if other kids at school were using them.

Dr. Anjan Chatterjee, a neuroscientist at the University of Pennsylvania, predicted that the use of these drugs and other "neuro-enhancing" products and procedures will continue to grow in popularity as they become available, he said in the Nature report. One reason that use of these drugs is on the rise is that they don't rely on training of medical specialists, he noted.

About 50 percent of those taking these drugs reported unpleasant side effects, including headaches, jitteriness, anxiety and sleeplessness. These side effects made some people stop using the drugs.

More information

To learn more about so-called "smart drugs," visit the University of Washington.



SOURCE: Nature, April 10, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Unlikely to Meet Target for TB Elimination
2. Switching to MA Coverage Unlikely for Current Beneficiaries With MediGap or Medicare Only
3. R rating might be unlikely to affect teens exposure to smoking in movies
4. Finasteride unlikely to induce high grade prostate cancers
5. National Healthcare Decisions Survey: Its Easier to Talk About Drugs and Sex Than End-of-Life Planning
6. Pennsylvania Health Plans Employ Various Strategies to Combat Cost of Specialty Drugs
7. Faster Test Detects Fake Tamiflu Drugs
8. Nanomachine Releases Anticancer Drugs Inside Cells
9. Fred Meyer, QFC Introduce $4 Generic Drugs
10. Ralphs Introduces $4 Generic Drugs
11. Indiana Adopts Legislation to Combat Illegitimate Online Pharmacies, Protect Residents From Counterfeit Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Unlikely Drugs Emerge as 'Cognition Enhancers'
(Date:4/29/2016)... ... 29, 2016 , ... Spine Team Texas, a comprehensive spine physician group specializing ... their physicians has been invited to be a featured speaker at the Texas Society ... on April 30, 2016. , Dr. R. Scott McPherson, a physical medicine and ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent Marketing ... an exercise invention which aids in proper muscle development. , "The Gym & ... Creative Director of World Patent Marketing. "Globalization has threatened the future growth of ...
(Date:4/29/2016)... ... 29, 2016 , ... Dr. Robert Mondavi, one of the dentists in ... is a fast-growing field as more patients are discovering the many different ways they ... the options currently available to them and which ones might work for their smiles. ...
(Date:4/29/2016)... ... 2016 , ... For those who skip meals occasionally (which is pretty much ... the many new lifestyle diet tips offered by nutritionists Pam Bonney and Priya Lawrence ... radio show. Bonny and Lawrence noted that because proper nutrition, including water, provides energy ...
(Date:4/29/2016)... Tampa, Fla. (PRWEB) , ... April 29, 2016 , ... ... Business Journal’s Best Places to Work employee satisfaction survey, earning them second place for ... local businesses with 25-49 employees. , “This is a great accomplishment for our ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016   Acsis , a ... that leading IT market research and advisory firm IDC ... the IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software ... report provides an assessment of the capabilities and business ... trace software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... Avril 2016   ... +5% sur le trimestre, soutenu par une croissance ... Croissance de +16% des ventes aux hôpitaux ... Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur ... aujourd,hui son chiffre d,affaires pour le premier trimestre ...
Breaking Medicine Technology: